Oily Fish Consumption Can Lower CVD Risk in Individuals With Family History
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 3, 2024 -- There is a significant interaction between biomarkers of low eicosapentaenoic/docosahexaenoic acids (EPA/DHA) intake and a family history of cardiovascular disease (CVD) in relation to long-term CVD risk, according to a study published online Dec. 4 in Circulation.
Federica Laguzzi, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues assessed interactions between biomarkers of low polyunsaturated fatty acids intake (PUFA levels ≤25th percentile) and family history (having at least one first-degree relative who experienced a CVD event) in relation to long-term CVD risk in a cohort of 40,885 CVD-free adults.
The researchers observed a significant interaction between low EPA/DHA and family history after multivariable adjustment (product term pooled relative risk, 1.09; 95 percent confidence interval, 1.02 to 1.16; P = 0.01). The pooled relative risk (95 percent confidence interval) of CVD was 1.41 (1.30 to 1.54) for combined exposure to low EPA/DHA and family history, while it was 1.25 (1.16 to 1.33) and 1.06 (0.98 to 1.14) for family history alone and EPA/DHA alone, respectively, compared with neither exposure.
"Low blood/tissue levels of n-3 EPA/DHA, reflecting a low intake of fats present in oily fish, may potentiate the risk of CVD in those already at increased risk because of family history," the authors write. "Although these results should be interpreted with caution, it seems reasonable to conclude that our results support the current cardiovascular prevention guidelines regarding the consumption of foods rich in n-3 EPA/DHA (i.e., oily fish), especially for people with a family history of CVD."
One author disclosed ties to Pharmavite.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.